Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Granzyme B (C11 or CTLA 1) Expected To Boost at high CAGR during 2017 To 2022

Granzyme B (C11 or CTLA 1)

Summary 

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) – Granzyme B is a serine protease secreted by granules of cytotoxic lymphocytes (CTLs), natural killer cells (NK cells) and cytotoxic T cells. Granzyme B is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. It activates the intracellular cascade of caspases finally resulting in the killing of the target cells. The molecules developed by companies in Preclinical and Discovery stages are 8 and 2 respectively. Report covers products from therapy areas Dermatology, Immunology, Cardiovascular, Metabolic Disorders, Central Nervous System, Oncology and Toxicology which include indications Diabetic Foot Ulcers, Aortic Aneurysm, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Hypertrophic Scars, Keloids, Skin Ulcers, Wounds, Abdominal Aortic Aneurysms, Alopecia, Dermal Ulcers, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Radiodermatitis, Rheumatoid Arthritis and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics development with respective active and dormant or discontinued projects.

@ http://www.wiseguyreports.com/sample-request/1473954-granzyme-b-c11-or-ctla-1-or-cathepsin-g-like-1

Scope of the Report

– The report provides a snapshot of the global therapeutic landscape for Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) 
– The report reviews Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 

  Table of Contents 

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) – Overview 
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) – Therapeutics Development 
Products under Development by Stage of Development 
Products under Development by Therapy Area 
Products under Development by Indication 
Products under Development by Companies      .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473954-granzyme-b-c11-or-ctla-1-or-cathepsin-g-like-1

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

See Campaign: https://www.wiseguyreports.com/reports/1473954-granzyme-b-c11-or-ctla-1-or-cathepsin-g-like-1
Contact Information:
Contact Us: NORAH TRENT Partner Relations & Marketing Manager [email protected] www.wiseguyreports.com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Tags:
, Research Newswire, Press Release, North America, South America, United States, Latin America, English

image


This post first appeared on ICrowdNewswire -, please read the originial post: here

Share the post

Granzyme B (C11 or CTLA 1) Expected To Boost at high CAGR during 2017 To 2022

×

Subscribe to Icrowdnewswire -

Get updates delivered right to your inbox!

Thank you for your subscription

×